Track topics on Twitter Track topics that are important to you
Late John Mendlein Joins Reinventing Biotech Lineup April PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Late John Mendlein Joins Reinventing Biotech Lineup April articles that have been published worldwide.
We have published hundreds of Late John Mendlein Joins Reinventing Biotech Lineup April news stories on BioPortfolio along with dozens of Late John Mendlein Joins Reinventing Biotech Lineup April Clinical Trials and PubMed Articles about Late John Mendlein Joins Reinventing Biotech Lineup April for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Late John Mendlein Joins Reinventing Biotech Lineup April Companies in our database. You can also find out about relevant Late John Mendlein Joins Reinventing Biotech Lineup April Drugs and Medications on this site too.
The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on tar...
With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman ...
"In the long run," the economist John Maynard Keynes wryly observed in his 1923 A Tract on Monetary Reform, "we are all dead." Given the logistic barriers to performing long-term studies of immunosuppression in kidney-transplant recipients, as well as the associated expense, many transplant professionals are similarly pessimistic about how to determine adequate long-term regimens in the current era, in which short-term results are excellent but late transplant loss remains a vexing problem. More than 14,000...
Those afflicted bark like dogs, scramble on all fours and loiter around graveyards - canine madness, referred to as kynanthropy, was an illness concept in its own right in the medicine of late antiquity. At roughly the same time as the medical description produced by Aëtius of Amida, the Syrian chronicler John of Ephesus, also from Amida, reported an epidemic of dog-like madness sweeping his home town in ad 560. The symptoms are identical and both authors are from Amida - what is the connection between the...
In recent decades, social scientists have shown that the reliability of eyewitness identifications is much worse than laypersons tend to believe. Although courts have only recently begun to react to this evidence, the New Jersey judiciary has reformed its jury instructions to notify jurors about the frailties of human memory, the potential for lineup administrators to nudge witnesses towards suspects that they police have already identified, and the advantages of alternative lineup procedures, including bli...
In the late 18th and early 19th centuries, Dr. John Howship, a pioneering British surgeon, described the clinical features and pathophysiology of various surgical disorders of the human body. His critical contributions to pediatric neurosurgery came in 1816 when he first described the features of an important childhood condition following head trauma, what he referred to as parietal bone absorption. This condition as depicted by Dr. Howship was soon to be christened by later scholars as traumatic cephalhydr...
Diabetes mellitus is a chronic disease that affects over 382 million people worldwide. Type-1 Diabetes (T1D) is classified as an autoimmune disease that results from pancreatic β-cell destruction and insulin deficiency. Type-2 Diabetes (T2D) is characterized principally by insulin resistance in target tissues followed by decreased insulin production due to β-cell failure. It is challenging to identify immunological markers such as inflammatory molecules that are triggered in response to changes during the...